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Results
•Gladwin, et al. (2011) performed a randomized controlled trial 
(RCT) entitled Nitric Oxide for Inhalation in the Acute Treatment of 
Sickle Cell Pain Crisis. This study enrolled 150 patients and 
randomized them to groups of either nitrogen with oxygen or NO 
with oxygen. They found that time to VOC resolution was not 
altered by use of NO (p=0.87), and neither were the outcomes of 
pain score, amount opioid needed, length of hospital stay, and 
number returning in 30 days (p values between 0.08 and 0.90). No 
harm or toxicity was seen.
• Weiner, et al. (2003) conducted an RCT entitled Preliminary
Assessment of Inhaled Nitric Oxide for Acute Vaso-Occlusive Crisis 
in Pediatric Patients with Sickle Cell Disease. They enrolled 
pediatric patients randomized into groups of 10 receiving either 
oxygen alone or NO mixed with oxygen. They found that there were 
decreased pain scores and lower amounts of pain medication 
Used (p= 0.37 and 0.15). These were not statistically significant 
results but may suggest a clinical significance. No harm or toxicity 
was seen.
• Head, et al. (2010) conducted an RCT entitled Beneficial Effects 
of Nitric Oxide Breathing in Adult Patients with Sickle Cell Crisis. 
This study enrolled adult patients and randomized them into groups 
of 9 receiving either oxygen alone or NO mixed with oxygen. Their 
results showed decreased pain scores in the treatment group (p= 
0.0376). They also reported decreased amount of pain medication 
used, though this was not statistically significant (p=0.26). No harm 
or toxicity was seen.
Introduction
•Sickle Cell Disease (SCD) is an autosomal recessive disease 
most often diagnosed in people of African descent (Natarajan, 
Townes, & Kutlar, 2010). Between 70,000-100,000 people in 
the United States alone were affected with SCD as of 2010 
(Centers for Disease Control and Prevention [CDC], 2010).
• The causative problem in Sickle Cell Disease (SCD) is the 
sickling, or change in shape, of red blood cells (RBC) due to 
abnormal hemoglobin contained within them. This abnormal 
hemoglobin, Hb S, amasses into polymers, causing a collection 
which alters the shape of the RBC. Accordingly, these crescent 
moon, or sickle, shaped RBCs are more prone to causing 
obstruction in vessels. This leads to low oxygen supply to 
tissues, ultimately resulting in tissue death. This blockage is 
what causes acute vaso-occlusive crisis (VOC), primarily noted 
by pain.
• Nitric oxide (NO) causes vasodilation and anti-inflammatory 
effects. Since it is inflammation and decreased vasodilation that 
are thought to be causative agents in VOC, NO is contemplated 
as potentially therapeutic. Low levels of NO are shown to 
correlate to increased pain levels. Current treatments are 
medications such as morphine.
Purpose
•The purpose of this study was to perform a systematic review 
of the literature on the effect of nitric oxide on pain control for 
patients experiencing acute vaso-occlusive crisis in sickle cell 
disease. The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) tool developed by the 
GRADE Working Group will be used to evaluate the evidence. 
Method
•An exhaustive literature search was conducted using PubMed, 
NLM Gateway, Medline, and EBM Multifile. Medline and 
EBM Multifile were accessed through the Pacific University 
Library system. The following keywords were searched 
individually and in combination: “sickle cell”, “pain”, and 
“nitric oxide”. The search was limited to human subjects and 
the English language. 
•The initial results included 156 articles. Articles older than ten 
years were excluded, which limited the number of available 
articles to 146. Book entries, drug information databases, 
current clinical trial notes, and hazardous substance database 
entries were excluded. Of the resulting 109 studies, only 
randomized control trials were included, and of those, only 
studies investigating effect of inhaled nitric oxide (NO) in acute 
sickle cell crisis pain, not asthma or NO exhalation, were 
reviewed. This resulted in the final three studies which were 
included in the final analysis.
Conclusion
•An overall grade of moderate tells us that there would be a great 
benefit from further studies in this area (Guyatt  et al., 2008). At this 
point, it is difficult to clearly state that inhaled NO does or does not 
decrease pain in acute VOC in patients with sickle cell disease. At 
present, larger studies need to be conducted as randomized controlled 
trials to further the available knowledge in this possible treatment.
• For now, it is suggested that clinicians consider the use of inhaled 
NO in sickle cell patients experiencing acute VOC, keeping in mind 
that the current data is conflicting as to efficacy. No adverse side 
effects from inhaled NO have been seen, and some patients have 
reported decreased pain from treatment; even if not shown to be 
statistically significant, this could be important to the patient in 
question. Given the recurrent nature of this condition, a patient may 
discover that this particular treatment is effective for him or her and 
may prefer to use it. Therefore, the option should currently be based 
not only on physician preference, but also on patient preference. To 
put it simply, it could be beneficial to a patient, and it certainly will 
not harm them. 
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Discussion 
•The Weiner, et al. (2003) study was one of two to suggest a positive effect of inhaled NO. Limitations included study size, the 
subjective endpoint of pain, and possible hydroxyurea use. One major limitation noted for this study is the fact that, despite 
having positive outcomes, they had a p value of 0.05 at best, with a p of 0.05 being statistically significant. Thus, none of their 
outcomes were statistically significant, though there was a trend heading towards statistical significance seen especially in the 
third hour of the study. 
• The Head et al. (2010) study was nearly a duplicate of Weiner, et al’s, with the major change being the enrollment of adults 
only. The limits of this study are, therefore, similar to the first. One other mentionable limitation is the fact that the authors found 
slightly less use of narcotic pain medication in the NO treatment group, but since this result was not found to be statistically 
significant, the results were seen as unimportant. 
•The Gladwin et al. (2011) study was the largest by far. The authors admit that their results include wide confidence intervals, 
which may call the significance of their negative results into question.
• In order to assess the quality of these studies, the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) tool was used. The first and main outcome was the measurement of changes in pain, and was started as a high grade 
but downgraded to moderate due to lack of consistency. The second outcome measured was the amount of pain medication used, 
and was also started at a grade of high and later downgraded to moderate due to lack of consistency. The third outcome 
measured was length of hospital stay, and only two of the studies evaluated this outcome. This outcome was similar to the first 
two in that it was started at a grade of high and downgraded to moderate due to lack of consistency. The level of methemoglobin 
in the blood was a fourth outcome measured as a potential toxicity, as well as the outcome of harm in general which included 
blood pressure, oxygen saturation, and other laboratory levels. These started and ended at a grade of high. 
• As two of the primary outcomes were measured as moderate and one (harm and methemoglobin levels together) as high, as 
well as the fact that three out of five outcomes measured as moderate evidence, the overall grade for the evidence was considered 
to be moderate.
